RheumNow Live 2023 Pre-Learn Survey

Please complete this series of True-False questions to prepare for RheumNow.live on March 18th and 19th.  Each Question has a Teaching Point evident by your answer – either True (evident as is) or False (the converse is true).  This “Pre-learn” survey will take 10 minutes. Lastly, you can also download the reading material each speaker has chosen for you to read prior to the meeting by clicking on the RheumNow Live Logo at the end of the survey.

Higher rates of pre-eclampsia, cesarean section and preterm birth are seen with PsA pregnancies.

Pregnant psoriatic arthritis patients are likely to increase or worsen disease activity after delivery compared to during pregnancy.

Hydroxychloroquine should be discontinued during pregnancy and breastfeeding

Hydroxychloroquine is FDA-approved for SLE, discoid lupus and rheumatoid arthritis.

Guidelines suggest PsA remission should be assessed by DAPSA or MDA.

The surface of hand/palm represents ~1% of your body surface area (BSA) when assessing the extent of psoriasis.

Pre-clinical RA patients produce increased ACPA in the lung.

One successful clinical trial demonstrating equivalence of biosimilar to its reference product can result in FDA approval of the biosimilar for multiple indications.

Amongst the oral DMARDs, methotrexate has the least effect on vaccine responses.

Assessing GCA, the MRA is better at damage, while FDA-PET better detects activity/inflammation.

Cardiac involvement is more common in GPA than EGPA

In the USA, ~20% have chronic low back pain

First degree relatives of AS patients have a 4-11% risk of developing AS

Between MRI and CT scan, MRI has the best accuracy in diagnosing sacroiliitis.

Over 5 years, 16% of nonradiographic AxSpA will progress to radiographic AxSpA

Compared to available biologics, JAK inhibitors are better at controlling psoriasis, more so than psoriatic arthritis.

Deucravacitinib is more effective than apremilast in treating plaque psoriasis

Treatment with IV rituximab reduces circulating BAFF levels (B Cell Activating Factor)

Interferon alpha is the biologic target of belimumab

In 2021 ACR guidelines, low dose ASA is recommended for GCA patients with vertebral or carotid artery involvement.

×